Get the Stockscreener App
839.96
14.30%
105.06
After Hours:
844.00
4.04
+0.48%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $839.96, with a volume of 10.84M.
It is up +14.30% in the last 24 hours and up +1.84% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$734.90
Open:
$840.8
24h Volume:
10.84M
Relative Volume:
2.98
Market Cap:
$677.40B
Revenue:
$45.04B
Net Income/Loss:
$10.59B
P/E Ratio:
71.73
EPS:
11.71
Net Cash Flow:
$414.30M
1W Performance:
+16.51%
1M Performance:
+1.84%
6M Performance:
-8.41%
1Y Performance:
+11.88%
1-Day Range:
$821.84
$858.00
1-Week Range:
$711.98
$858.00
52-Week Range:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Lilly Blasts Compounders' 'Scattershot' Bid To Reverse FDA - Law360
Eli Lilly (LLY) Boosts U.S. Manufacturing with Promising Weight-Loss Pill - GuruFocus
Eli Lilly plans to make weight-loss pill in U.S. amid Trump’s reshoring push (NYSE:LLY) - Seeking Alpha
Eli Lilly (NYSE:LLY) Advances Diabetes Treatment And Partners With BigHat On Antibody Discovery - Yahoo Finance
Lilly says new daily pill can help with weight loss, blood sugar - NewsNation
Daily GLP-1 Pill Shows Promise for Diabetes and Weight Loss, Eli Lilly Says - Verywell Health
First Weight-Loss Pill From Lilly Shows Promising Results - Wyoming Tribune Eagle
Lilly Promises to Make Weight-Loss Pill in US in Reshoring Push - Bloomberg.com
Eli Lilly and Company (LLY): One of the Best Long Term Stocks to Buy According to Billionaires - Insider Monkey
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal - Pharmaceutical Technology
Top-Line Results Positive for Lilly’s Oral Orforglipron - Medscape
Lilly's orforglipron consistent with injectable GLP-1 medicines in Phase 3 trial - MSN
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar - The New York Times
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (April 2025) - 24/7 Wall St.
Where Will Eli Lilly Be in 5 Years? - The Motley Fool
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
Why Eli Lilly and Company (LLY) is Skyrocketing? - Insider Monkey
Eli Lilly (LLY) Surges on Promising Obesity Pill Trial Results - GuruFocus
Eli Lilly develops groundbreaking new weight-loss pill - NBC News
Eli Lilly (LLY) Shares Surge on Promising New Weight-Loss Pill - GuruFocus
Lilly Soars After Pill Shows Its as Good as Ozempic - Bloomberg.com
Eli Lilly's obesity drug trial shows 7.3kg weight loss, boosts market competitionCHOSUNBIZ - Chosunbiz
Friday Five – Lilly's obesity oral could eat up competition, pill penalty pivot, tariff talk…and more - FirstWord Pharma
Experimental GLP-1 pill helped people with diabetes lose weight and lower blood sugar, Eli Lilly says - WTOP
Chugai Highlights Eli Lilly’s Promising Phase 3 Results for Orforglipron - TipRanks
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Eli Lilly: Experimental GLP-1 pill for diabetes helped with weight loss, blood sugar - Yahoo
Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase III - BioWorld MedTech
Eli Lilly shares jump 14% on positive results for its ’Ozempic in a pill’ - Investing.com
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React - Benzinga
Lilly weight-loss pill works as well as Ozempic, shares surge - MSN
How Eli Lilly's GLP-1 pill could transform the weight-loss space - Yahoo Finance
Eli Lilly's Obesity Trial Triumph Boosts Shares, While UnitedHealth Stumbles - Finimize
U.S. Markets Closed Mixed Thursday As Eli Lilly Led, Webull Lagged - Barron's
Lilly soars after weight-loss pill results rival Ozempic’s - The Detroit News
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock - Benzinga
Eli Lilly announces successful trial of weight-loss, diabetes pill - Yahoo
Eli Lilly’s stock soars 13% after reporting positive data from trial of diabetes and weight-loss pill - MSN
Daily GLP-1 pill effective for diabetes and obesity, Eli Lilly says - AOL.com
Weight-loss drug news sends Eli Lilly stock soaring - TheStreet
Lilly shares soar on new weight-loss pill that looks to pass Ozempic - Orange County Register
Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results - WSJ
Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade - Yahoo Finance
Eli Lilly announces trial results of new weight loss, diabetes pill; stock booms - MSN
New Eli Lilly-made GLP-1 pill could work as well as its injectable Mounjaro, Zepbound - Washington Times
Eli Lilly daily diabetes pill could be as effective as Ozempic and Mounjaro, trial finds - Spectrum News
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential - Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide - Yahoo
Lilly’s obesity pill scores in large diabetes trial - BioPharma Dive
Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic - New York Post
Eli Lilly's new GLP-1 weight loss pill showed success in clinical trial - LiveNOW from FOX
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.31%
7.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):